52 Week Range
As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Dr.Reddy's Laboratories Posts Dec-Qtr Consol Net Loss
India's Dr.Reddy's Laboratories Posts Dec-Qtr Consol Net Loss
Dr.Reddy's Laboratories Launches Sodium Nitroprusside Injection In U.S. Market
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
8-2-337, Road No.3 Banjara Hills
Satish K. Reddy
Chairman of the Board
G. V. Prasad
Co-Chairman of the Board, Chief Executive Officer, Managing Director
President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
Chief Executive Officer, North America Generics
M. V. Ramana
Chief Executive Officer, Branded Markets (India and Emerging Markets)
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets.
Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, driven by strong growth in emerging markets.
* Shares give back early gains to trade lower (Adds details on the company's drugs, background, comments)
Dr.Reddy's Laboratories posted a better-than-expected rise in second-quarter profit as higher sales in some emerging countries offset a marginal decline in business in North America, a key market for the Indian generic drugmaker.
Indian generic drugmaker Dr.Reddy's Laboratories Ltd <REDY.NS> posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.
Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the launch of a generic version of an opioid addiction drug.
Indivior shares fell more than 20 percent after the British drugmaker warned of a bigger-than-expected blow from a copycat of its top opioid addiction treatment and posted weak initial sales from its new blockbuster prospect.
Indivior <INDV.L> shares fell more than 20 percent on Wednesday after the British drugmaker warned of a bigger-than-expected blow from the launch of a copycat of its best-selling opioid addiction treatment.
British drugmaker Indivior <INDV.L> warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.
Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.
Indivior Plc <INDV.L> got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.
British drugmaker Indivior Plc said on Friday a U.S. court extended the restraining order blocking Indian pharmaceutical firm Dr.Reddy's Laboratories from launching a generic version of its bestselling opioid addiction treatment in the United States.
Shares in drugmaker Indivior <INDV.L> rose on Monday after a U.S. Court granted a temporary restraining order blocking Dr. Reddy's Laboratories <REDY.NS> from launching a generic version of Indivior's best-selling opioid addiction treatment.
Indian shares ended slightly higher on Tuesday, driven by gains in Dr. Reddy's Laboratories Ltd and State Bank of India (SBI) following their quarterly results.
Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 19 percent drop in quarterly net profit on Tuesday, missing analysts' estimates, pulled down by headwinds in the U.S. market.
Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an about 19 percent fall in quarterly net profit, missing estimates, hurt by headwinds in the U.S. market.
* GETS ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR API MIRFIELD PLANT, UK Source text for Eikon: Further company coverage:
* SAYS GETS EIR FROM US FDA FOR API CUERNAVACA PLANT IN MEXICO Source text: https://bit.ly/2H9URmM Further company coverage:
* CO, U.S. UNIT PROMIUS PHARMA ANNOUNCE FILING OF AN NDA FOR MIGRAINE CANDIDATE
* CHIEF OPERATING OFFICER ABHIJIT MUKHERJEE TO RETIRE ON MARCH 31
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.